PCM
ARQT icon

Pavaki Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Pavaki Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9M Hold
187,000
– – 1.71% 13
2026
Q1 		$4.41M Sell
187,000
-15,000
-7% -$383K 1.87% 13
2025
Q4 		$5.87M Buy
+202,000
New +$5.17M 2.3% 9

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pavaki Capital Management's ARQT Position: Q2 2026 in Review

Pavaki Capital Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 187,000 shares worth $4.9M. The position accounts for 1.71% of the portfolio, ranked #13.

Pavaki Capital Management first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.87M in Q4 2025. 249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Pavaki Capital Management held 187,000 shares of Arcutis Biotherapeutics worth $4.9M as of Q2 2026.
  • Pavaki Capital Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 1.71% of Pavaki Capital Management's portfolio in Q2 2026, its #13 holding.
  • Pavaki Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Arcutis Biotherapeutics position peaked at $5.87M in Q4 2025.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.